Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 3
1992 1
1993 1
1995 1
1996 3
1997 1
1999 1
2000 4
2001 4
2002 5
2003 8
2004 6
2005 1
2006 7
2007 9
2008 3
2009 10
2010 7
2011 5
2012 14
2013 6
2014 13
2015 13
2016 13
2017 7
2018 10
2019 12
2020 9
2021 15
2022 12
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma"
Page 1
European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders.
Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. Al-Toma A, et al. United European Gastroenterol J. 2019 Jun;7(5):583-613. doi: 10.1177/2050640619844125. Epub 2019 Apr 13. United European Gastroenterol J. 2019. PMID: 31210940 Free PMC article.
In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline also deals with other gluten-related disorders, such as dermatitis herpetiformis, which is a cutaneous manifestation of CD characteri …
In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline …
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Patients were randomly assigned (1:1) using an interactive voice web response system to mogamulizumab (1.0 mg/kg intravenously on a weekly basis for the first 28-day cycle, then on days 1 and 15 of subsequent cycles) or vorinostat (400 mg daily). Stratification was by cutaneou …
Patients were randomly assigned (1:1) using an interactive voice web response system to mogamulizumab (1.0 mg/kg intravenously on a weekly b …
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L. Shustov A, et al. Cancer Treat Res. 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. Cancer Treat Res. 2019. PMID: 30596216 Review.
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes t …
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature …
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
BACKGROUND: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. ...
BACKGROUND: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. …
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R. Prince HM, et al. Ann Hematol. 2023 Jan;102(1):13-29. doi: 10.1007/s00277-022-05054-9. Epub 2022 Dec 13. Ann Hematol. 2023. PMID: 36512081 Free PMC article. Review.
CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some cutaneous T-cell lymphomas. ...Further research is required on brentuximab vedotin treatme …
CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell …
Transplantation.
Zain J. Zain J. Cancer Treat Res. 2019;176:269-287. doi: 10.1007/978-3-319-99716-2_13. Cancer Treat Res. 2019. PMID: 30596223
Mature T-cell non-Hodgkin lymphomas (T-cell NHL) are a heterogeneous group of lymphoid malignancies including NK/T-cell lymphomas. ...Allogeneic stem cell transplantation harnesses the graft-versus-lymphoma effect, providing long-t …
Mature T-cell non-Hodgkin lymphomas (T-cell NHL) are a heterogeneous group of lymphoid malignancies including NK …
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Clinical Trial.
BACKGROUND: The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for imm …
BACKGROUND: The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allog …
New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ. Scarisbrick JJ. Curr Opin Oncol. 2016 Sep;28(5):384-9. doi: 10.1097/CCO.0000000000000311. Curr Opin Oncol. 2016. PMID: 27390044 Review.
PURPOSE OF REVIEW: Currently, there are no curative therapies for cutaneous T-cell lymphoma (CTCL), and consecutive treatments tend to be given until loss of response. ...This article reviews new drugs available for CTCL. RECENT FINDINGS: CTCL encompas …
PURPOSE OF REVIEW: Currently, there are no curative therapies for cutaneous T-cell lymphoma (CTCL), and consecut …
Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V, Zhou Y. Van-de-Velde V, et al. J Cutan Med Surg. 2019 May/Jun;23(3):319-327. doi: 10.1177/1203475419840629. Epub 2019 Apr 3. J Cutan Med Surg. 2019. PMID: 30943788 Review.
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration of malignant monoclonal T lymphocytes into the skin. ...Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, received extended approval …
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration o …
Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P, Wang Y. Lai P, et al. Cancer Biol Med. 2021 Feb 15;18(1):34-51. doi: 10.20892/j.issn.2095-3941.2020.0216. Cancer Biol Med. 2021. PMID: 33628583 Free PMC article. Review.
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. ...These epigenetic regulators are essential in the development of CTCL and provide new insights into the clinical treatments of this refractory disease. …
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. ...These epigenetic …
186 results